Welcome to our dedicated page for Heron Therapeutics SEC filings (Ticker: HRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Heron Therapeutics, Inc. (HRTX) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Nasdaq‑listed commercial-stage biotechnology company, Heron uses Forms 10‑K, 10‑Q, 8‑K, and proxy statements on Schedule 14A to report financial results, material events, and governance matters related to its acute care and oncology supportive care business.
Investors reviewing HRTX SEC filings can examine current reports on Form 8‑K that disclose items such as quarterly and year‑to‑date financial results, capital restructuring transactions, amendments to credit facilities with Hercules Capital, Inc., exchange and issuance of convertible senior unsecured promissory notes, private placements of common and preferred equity, and adoption of a Tax Benefit Preservation Plan intended to protect net operating loss carryforwards. Other 8‑K filings describe material agreements, manufacturing and supply arrangements with Patheon, office lease commitments for corporate headquarters, and changes in the composition of the Board of Directors.
Heron’s proxy statements on Schedule 14A provide detail on stockholder meetings, including special meetings to approve the issuance of common stock upon conversion of convertible notes and Series A Convertible Preferred Stock under Nasdaq Listing Rule 5635(d). These documents explain voting procedures, virtual meeting logistics, and the specific proposals presented to stockholders.
Through this page, users can also track governance and capital structure disclosures such as the creation of Series A Convertible Preferred Stock and Series B Preferred Stock, rights plans, and cooperation agreements with significant investors. Stock Titan enhances these filings with AI‑powered summaries that highlight key terms, financial implications, and governance changes, helping readers quickly understand complex agreements without replacing the full legal text. Real‑time updates from EDGAR ensure that new HRTX filings, including 10‑K annual reports, 10‑Q quarterly reports, and Form 4 insider transaction reports when available, are surfaced promptly for further analysis.
Heron Therapeutics executive William P. Forbes exercised restricted stock units into common shares in a routine compensation-related move. On April 19, 2026, he converted 3,874 restricted stock units, receiving the same number of common shares at a stated price of $0.00 per share, reflecting vesting rather than an open-market purchase or sale.
Following this transaction, Forbes directly held 185,647 shares of common stock and 27,120 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock, and the units vest in 16 equal quarterly installments beginning one quarter after the January 19, 2024 grant date.
Heron Therapeutics Chief Executive Officer Craig A. Collard exercised restricted stock units into common shares as part of his equity compensation. He converted 13,797 restricted stock units into 13,797 shares of common stock at a stated price of $0.00 per share.
After the transaction, he directly holds 662,052 shares of common stock and 96,758 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock and vests in 16 equal quarterly installments beginning one quarter after the January 19, 2024 grant date.
Heron Therapeutics EVP and CFO Ira Duarte exercised restricted stock units to receive additional common shares as equity compensation. On this date, 3,874 restricted stock units converted into 3,874 shares of common stock at a stated price of $0.00 per share.
Following the transaction, Duarte directly held 215,876 shares of common stock and 27,120 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock and vests in 16 equal quarterly installments beginning one quarter after the January 19, 2024 grant date.
A footnote also notes that Duarte’s holdings include 16,646 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2025, highlighting ongoing participation in both stock purchase and equity award programs.
Heron Therapeutics, Inc. is soliciting proxies for its 2026 Annual Meeting to be held remotely on June 11, 2026 to elect seven directors and vote on six proposals. Material votes include approval to increase equity from the 2007 Amended and Restated Equity Incentive Plan by 16,560,000 shares and to amend the ESPP to add 10,000,000 shares. The record date for voting was April 14, 2026, when 188,638,866 shares were outstanding. The proxy also seeks ratification of Withum as auditor, a nonbinding say-on-pay for 2025 executive compensation, and ratification of the Tax Benefits Preservation Plan. The proxy discloses related-party financing in 2025, including a private placement and issuance of senior unsecured convertible notes due 2031.
Heron Therapeutics Chief Executive Officer Craig A. Collard exercised 62,500 restricted stock units into 62,500 shares of common stock. The RSUs carried a $0.0000 exercise price and each unit represented a right to receive one share of common stock.
After the transaction, Collard directly owned 648,255 shares of Heron Therapeutics common stock. His holdings include 14,045 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2025. The restricted stock units vest in four equal annual installments beginning one year after the grant date, contingent on his continued service.
Heron Therapeutics, Inc. updated employment and retention arrangements for its senior leadership team. CEO Craig Collard’s amended agreement increases severance protections and equity vesting if he is terminated without cause or resigns for good reason, including enhanced cash payments, accelerated stock vesting and extended company-paid health coverage, with larger benefits during a change in control window. The company also amended and restated management retention agreements for its CFO, Chief Development Officer and Chief Operating Officer, aligning their severance, change in control equity vesting, and 24‑month non‑competition and non‑solicitation covenants, and updating bonus, arbitration and North Carolina governing law provisions.
The Vanguard Group filed an amendment to its Schedule 13G disclosing it beneficially owns 0 shares of Heron Therapeutics Inc. common stock, representing 0% of the class. The filing notes an internal realignment on January 12, 2026 that caused certain subsidiaries/divisions to report separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The amendment is signed by Ashley Grim as Head of Global Fund Administration on 03/27/2026.
Heron Therapeutics provides a detailed annual overview of its business, products, regulations and risks. The company is a commercial-stage biotech focused on acute care and oncology, selling four FDA‑approved drugs: ZYNRELEF, APONVIE, CINVANTI and SUSTOL, all built on proprietary drug‑delivery science.
The filing highlights heavy competition from generics and branded rivals, dependence on favorable Medicare and private payor reimbursement, and extensive FDA, pricing and anti‑fraud regulation. Heron also outlines its patent estate extending into the 2030s, reliance on third‑party manufacturers and single‑source suppliers, and a 128‑person workforce, most in sales and marketing.
Heron Therapeutics reported full-year 2025 net revenue of $154.9 million, up 7.4% from 2024, driven by rapid growth in its Acute Care franchise. Acute Care revenue rose 65.1% year-over-year to $49.6 million, including strong gains from ZYNRELEF and APONVIE, while Oncology revenue declined 7.8% to $105.3 million.
The company narrowed its loss from operations to $2.5 million in 2025 and improved adjusted EBITDA to $14.7 million from $6.4 million, reflecting better profitability despite a net loss of $20.2 million. Heron ended 2025 with $46.6 million in cash, cash equivalents, and short-term investments and guided 2026 net revenue to $173–$183 million with adjusted EBITDA of $10–$20 million.
Operationally, ZYNRELEF and APONVIE benefited from permanent CMS J-Codes and broader clinical recognition, supporting continued adoption. Management highlighted momentum entering 2026, pointing to expanding demand signals, improved reimbursement clarity, and a stronger commercial engine across Acute Care and Oncology products.
Clearline Capital LP and related filers reported a significant passive stake in Heron Therapeutics, Inc. They disclosed beneficial ownership of 12,235,239 shares of Heron common stock, representing 6.7% of the outstanding shares.
The ownership percentage is based on 183,362,522 shares of common stock reported as issued and outstanding as of October 30, 2025 in Heron’s Form 10-Q. The shares are held with shared voting and dispositive power among Clearline Capital LP, Clearline Capital LLC and Marc Majzner, with no sole voting or dispositive power reported.
The filers certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Heron Therapeutics, consistent with a passive Schedule 13G/A filing.